The global psoriasis treatment market size was valued at USD 29.26 billion in 2025. The market is projected to increase from USD 31.51 billion in 2026 to USD 59.89 billion by 2034, registering a compound annual growth rate (CAGR) of 8.36% during the forecast period. North America dominated the market, accounting for a 74.74% share in 2025.

Psoriasis is a chronic autoimmune inflammatory condition that causes skin cells to multiply rapidly, resulting in red, itchy, painful, and scaly patches. Growing awareness of psoriasis as a systemic inflammatory disease is encouraging patients to seek long-term treatment and improved disease management. Increasing adoption of targeted therapies, biologics, and advanced topical medications is also supporting market expansion.

Key Market Growth Drivers

Increasing Prevalence of Psoriasis

The rising prevalence of chronic psoriasis is generating sustained demand for effective treatment options. According to the National Psoriasis Foundation, approximately 125 million people worldwide, representing 2–3% of the global population, were affected by psoriasis. The growing patient population is increasing the need for topical medications, oral therapies, biologics, and other systemic treatments. Improved diagnosis and greater awareness are also encouraging patients to access professional dermatological care.

Rising Adoption of Biologics and Targeted Therapies

Increasing use of biologics and interleukin inhibitors is contributing significantly to market growth. These therapies target specific immune pathways involved in psoriasis and can provide improved skin clearance and long-term disease control, particularly for patients with moderate-to-severe conditions. Growing adoption of IL-17 and IL-23 inhibitors, alongside the introduction of biosimilars, is strengthening treatment availability and expanding therapeutic options.

Product Innovation and Drug Approvals

Pharmaceutical companies are investing in research and development to introduce innovative oral, injectable, and topical treatments. New drug approvals and clinical advancements are expanding treatment choices for patients who do not respond adequately to conventional medications. The development of targeted therapies with convenient administration schedules is further supporting market demand.

Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriasis-treatment-market-100600

A major trend is the increasing utilization of IL-17 and IL-23 inhibitors for moderate-to-severe psoriasis. Healthcare providers are increasingly focusing on deeper skin clearance, fewer disease flares, and sustained remission. Companies are also developing oral therapies and non-steroidal topical treatments to address different patient requirements.

Another notable trend is the expansion of biosimilar products. These alternatives can improve affordability and broaden access to biologic treatments. Strategic collaborations, clinical research, and regulatory approvals are also shaping competition and encouraging innovation across the market.

Market Segmentation

By Drug Class

The market is segmented into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, TYK2 inhibitors, JAK inhibitors, corticosteroids, vitamin D analogs, retinoids, and others. Interleukin inhibitors dominated the market due to their targeted mechanisms and growing use in moderate-to-severe psoriasis. The TYK2 inhibitors segment is projected to grow at a CAGR of 34.96% during the forecast period.

By Indication

Based on indication, the market includes plaque psoriasis, psoriatic arthritis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and others. Plaque psoriasis held the leading market position in 2025 because of its larger treated patient population and demand for topical, oral, and biologic therapies. The psoriatic arthritis segment is projected to register an 11.51% CAGR.

By Product Type and Route of Administration

By product type, the market is divided into biologics and non-biologics. Biologics accounted for the largest share, supported by their targeted action and use in patients requiring advanced treatment. By route of administration, the market is categorized into oral, parenteral/systemic, and topical therapies. Parenteral/systemic treatments dominated, while oral treatments are projected to grow at a CAGR of 14.24%.

By Age Group and Distribution Channel

The market is divided into adults and pediatrics. Adults dominated due to the larger treated patient population and established use of systemic therapies. By distribution channel, the segments include hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies. Specialty pharmacies held the leading position because biologics and advanced systemic treatments often require specialist prescriptions and monitoring. Online pharmacies are projected to grow at a CAGR of 16.08%.

Regional Outlook

North America

North America dominated the global market with a valuation of USD 21.87 billion in 2025. High diagnosis rates, established dermatology services, favorable access to advanced treatments, and widespread adoption of biologics and biosimilars support regional growth.

Europe

Europe represents an important regional market and is projected to grow at a CAGR of 7.82%. Established reimbursement frameworks, clinical guidelines, and increasing adoption of IL-17, IL-23, and advanced oral therapies are supporting demand.

Asia Pacific

Asia Pacific is witnessing market expansion due to its large patient population, improving diagnostic capabilities, rising healthcare expenditure, and broader access to dermatology services. Biosimilar launches and local pharmaceutical development are also supporting adoption.

Latin America and Middle East & Africa

These regions are expected to experience growth through increasing disease awareness, improved specialist care, and gradual expansion of access to systemic and biologic treatments.

Competitive Landscape

The global market features competition among pharmaceutical companies focused on innovative drug development, product approvals, biosimilar launches, and geographic expansion. Major players include AbbVie Inc., Novartis AG, Johnson & Johnson Services, Inc., Pfizer Inc., Eli Lilly and Company, LEO Pharma A/S, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Almirall S.A., and Arcutis Biotherapeutics, Inc.

Companies are strengthening their portfolios through clinical research, strategic collaborations, and new product introductions. The development of targeted oral therapies and more affordable biologic alternatives is also influencing competitive strategies.

Challenges and Opportunities

High treatment costs, particularly for biologics and advanced systemic therapies, remain a major market restraint. Reimbursement limitations and unequal access to specialist care can prevent patients from receiving newer treatments. However, increasing awareness in emerging economies, expansion of biosimilars, and development of affordable therapies offer significant growth opportunities.

Conclusion

The psoriasis treatment market is expected to expand steadily through 2034, supported by increasing disease prevalence, growing adoption of targeted biologics, and continuous pharmaceutical innovation. Although affordability and unequal access remain challenges, advancements in oral treatments, topical medications, and biosimilars are expected to create new opportunities for market participants.